Patents by Inventor Mohammed OUKKA

Mohammed OUKKA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND COMPOSITIONS FOR TREATING CANCER
    Publication number: 20230285556
    Abstract: Compounds, compositions, and methods for generating T cells with altered phenotype are disclosed. The phenotype-altered T cells have increased persistence, prolonged survival, and increased antitumor activity and are useful for treatment of cancers.
    Type: Application
    Filed: September 12, 2022
    Publication date: September 14, 2023
    Inventors: George A. Gaitanaris, Marc A. Gavin, Robert H. Lemus, Caglar Cekic, Mohammed Oukka, Trupti Vardam-Kaur
  • Selective differentiation, identification, and modulation of human TH17 cells
    Patent number: 9732320
    Abstract: The embodiments provide for the modulation of both the differentiation and activity of human TH17 cells. More specifically, human TH17 cell differentiation can modulated by TGF-? and IL-21, and their agonists and antagonists. Function of TH17 cells can be modulated by, for example, BLT1 or podoplanin, and their agonists and antagonists. Additionally, the embodiments provide for the identification of TH17 cells. More specifically, human TH17 cells specifically upregulate BLT1 and podoplanin.
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: August 15, 2017
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Vijay K. Kuchroo, David E. Anderson, Estelle Bettelli, David Hafler, Mohammed Oukka
  • SELECTIVE DIFFERENTIATION, IDENTIFICATION, AND MODULATION OF HUMAN TH17 CELLS
    Publication number: 20170159016
    Abstract: The embodiments provide for the modulation of both the differentiation and activity of human Th17 cells. More specifically, human Th17 cell differentiation can modulated by TGF-? and IL-21, and their agonists and antagonists. Function of Th17 cells can be modulated by, for example, BLT1 or podoplanin, and their agonists and antagonists. Additionally, the embodiments provide for the identification of Th17 cells. More specifically, human Th17 cells specifically upregulate BLT1 and podoplanin.
    Type: Application
    Filed: October 17, 2014
    Publication date: June 8, 2017
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Vijay K. KUCHROO, David E. ANDERSON, Estelle BETTELLI, David HAFLER, Mohammed OUKKA
  • SELECTIVE DIFFERENTIATION, IDENTIFICATION, AND MODULATION OF HUMAN TH17 CELLS
    Publication number: 20150050732
    Abstract: The embodiments provide for the modulation of both the differentiation and activity of human Th17 cells. More specifically, human Th17 cell differentiation can modulated by TGF-? and IL-21, and their agonists and antagonists. Function of Th17 cells can be modulated by, for example, BLT1 or podoplanin, and their agonists and antagonists. Additionally, the embodiments provide for the identification of Th17 cells. More specifically, human Th17 cells specifically upregulate BLT1 and podoplanin.
    Type: Application
    Filed: October 17, 2014
    Publication date: February 19, 2015
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Vijay K. KUCHROO, David E. ANDERSON, Estelle BETTELLI, David HAFLER, Mohammed OUKKA